Bonus Oct 18, 1999 Nov 05, 1999 Oct 07, 1999 Bonus Ratio: 2 share(s) for every 1 shares held Rights Feb 03, 1995 Mar 02, 1995 May 03, 1995 Rights ratio: 4 share for every 50 held at a price of Rs ...

Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is ...

Cipla's North American business achieved a record $250 million revenue in Q1 FY25, a 13% year-on-year growth. The company's branded prescription business in India grew 10%, while overall India growth ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Revenue 25,774.09 22,753.12 21,763.34 19,159.59 ...

Revenue 7,072.97 7,051.02 6,693.94 6,163.24 ...

Objective: The aim of this study was to compare the antihypertensive efficacy and tolerability of the calcium channel antagonist amlodipine besylate versus the angiotensin II type 1 receptor ...

VWAP, or volume-weighted average price, is a technical analysis tool used primarily on intraday charts. It provides a benchmark for the average price a security has traded at during the day ...

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market ...

Hikma is offering cisatracurium besylate injection in 200mg/20ml and 20mg/10ml doses. The product is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8716 ...

The global telmisartan market was valued at $3,453 million in 2019, and is projected to reach $4,258 million by 2027, registering a CAGR of 3.4% from 2020 to 2027. The growth of the global telmisartan ...